Roper Technologies Reports Mixed Q2 Results
Roper Technologies reported Q2 adjusted diluted earnings of $2.24 per share, up from $1.87 for the same period last year, and beating the Capital IQ consensus ...
Alkermes to Finish Rolling Submission of New Drug Application
Alkermes said early Monday it has initiated the rolling submission of a new drug application, seeking a marketing approval of ALKS 5461, an oral ...
